Affimed N.v Intrinsic Value Calculation – AFFIMED N.V Reports 81% Decrease in Total Revenue for FY2023 Q2

August 13, 2023

🌥️Earnings Overview

AFFIMED N.V ($NASDAQ:AFMD). reported a total revenue of EUR 1.4 million for the second quarter of FY2023, ending on June 30, 2023. This represents an 81.0% decrease from the same period last year. Net income for the quarter was EUR -29.4 million, compared to a loss of -19.4 million in the prior year’s quarter. The report was released on August 10, 2023.

Analysis – Affimed N.v Intrinsic Value Calculation

GoodWhale has conducted an analysis of AFFIMED N.V.’s fundamentals and determined that the intrinsic value of its share is approximately $2.8. This was calculated using our proprietary Valuation Line. Currently, AFFIMED N.V.’s stock is being traded at $0.5, representing a significant undervaluation of 81.8%. Therefore, this stock appears to be an attractive investment opportunity for those looking to buy at a discounted price. With a proper understanding of AFFIMED N.V.’s fundamentals and the potential of its share price increasing, investors can capitalize on this opportunity. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Affimed N.v. More…

    Total Revenues Net Income Net Margin
    31.95 -111.31 -347.1%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Affimed N.v. More…

    Operations Investing Financing
    -116.56 4.27 -4.27
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Affimed N.v. More…

    Total Assets Total Liabilities Book Value Per Share
    134.71 35.78 0.66
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Affimed N.v are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    31.3% -342.7%
    FCF Margin ROE ROA
    -366.5% -61.1% -50.8%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items




  • Peers

    The company’s products are based on its proprietary T cell engagement platform, which is designed to harness the body’s immune system to fight cancer. Affimed’s products are in clinical development for the treatment of solid tumors and hematologic malignancies. The company’s primary competitors are argenx SE, Fate Therapeutics Inc, and Syndax Pharmaceuticals Inc.

    – argenx SE ($NASDAQ:ARGX)

    The company’s market cap is 21.06B as of 2022 and its ROE is -18.8%. The company is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious and life-threatening diseases.

    – Fate Therapeutics Inc ($NASDAQ:FATE)

    Fate Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development of programmed cellular therapeutics for the treatment of cancer and other diseases. The company’s lead product candidate, FT516, is a universal, off-the-shelf natural killer cell product candidate that is being evaluated in a Phase 1 clinical trial in advanced solid tumor patients. Fate Therapeutics has a market cap of $1.89 billion and a return on equity of -28.5%.

    – Syndax Pharmaceuticals Inc ($NASDAQ:SNDX)

    Syndax is a clinical-stage biopharmaceutical company focused on the development of entinostat and other drugs for the treatment of cancer. As of 2022, the company’s market cap was $1.26 billion and its ROE was 0.48%. Syndax’s pipeline includes entinostat, an investigational HDAC inhibitor, which is in Phase III clinical trials for the treatment of breast cancer and non-small cell lung cancer. The company is also developing SNDX-6352, a Phase I/II clinical trial agent for the treatment of solid tumors, and SNDX-2952, a Phase II clinical trial agent for the treatment of ovarian cancer.

    Summary

    AFFIMED N.V reported a sharp decrease in total revenue for its second quarter of FY2023, with a 81.0% drop year-on-year. Net income for the quarter was reported at EUR -29.4 million, a further deterioration from the already negative EUR -19.4 million result reported in the same period last year. This marks a challenging time for potential investors in AFFIMED N.V as the company struggles to generate positive returns in spite of the challenging market conditions. While the company continues to explore ways to improve its financial performance, investors should remain vigilant and evaluate the risk-reward associated with investing in AFFIMED N.V.

    Recent Posts

    Leave a Comment